Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Megakaryocyte growth and development factor (MGDF): An Mpl ligand and cytokine that regulates thrombopoiesis
Autore:
Neumann, TAK; Foote, M;
Indirizzi:
Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA Amgen Inc Thousand Oaks CA USA 91320 lin Dev, Thousand Oaks, CA 91320 USA Amgen Inc, Med Writing, Thousand Oaks, CA 91320 USA Amgen Inc Thousand Oaks CA USA 91320 Writing, Thousand Oaks, CA 91320 USA
Titolo Testata:
CYTOKINES CELLULAR & MOLECULAR THERAPY
fascicolo: 1, volume: 6, anno: 2000,
pagine: 47 - 56
SICI:
1368-4736(200003)6:1<47:MGADF(>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; PHASE-I TRIAL; RECOMBINANT HUMAN INTERLEUKIN-11; CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA; BONE-MARROW TRANSPLANTATION; C-MPL; NONHUMAN-PRIMATES; PLATELET PRODUCTION; TYROSINE PHOSPHORYLATION; BLOOD-PLATELETS;
Keywords:
MGDF; thrombopoiesis; recombinant protein; platelet function;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
80
Recensione:
Indirizzi per estratti:
Indirizzo: Neumann, TAK Amgen Inc, Clin Dev, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA Amgen Inc 1 Amgen Ctr Dr Thousand Oaks CA USA 91320 91320 USA
Citazione:
T.A.K. Neumann e M. Foote, "Megakaryocyte growth and development factor (MGDF): An Mpl ligand and cytokine that regulates thrombopoiesis", CYTOK CELL, 6(1), 2000, pp. 47-56

Abstract

Megakaryocyte growth and development factor (MGDF) is a ligand for the Mplreceptor related to thrombopoietin (TPO). MGDF stimulates megakaryocytopoiesis and thrombopoiesis, and Is highly selective to cells bearing the Mpl receptor. Studies done in rodents, nonhuman primates, and humans have confirmed that MGDF can increase platelet counts in normal and chemotherapy- or radiotherapy-treated subjects. Platelet function and physiology remain normal after MGDF administration, with no effect on platelet aggregation. Pegylated recombinant human MGDF (PEG-rHuMGDF) was used clinically with initial success. Cancer patients receiving chemotherapy showed dose-dependent increases in platelet counts and increases in bone marrow megakaryocytes. Clinical development of PEG-rHuMGDF was halted owing to the formation of neutralizing antibodies in some patients and normal volunteers who received the drug. The application of exogenous recombinant Mpl ligands should be explored in the setting of randomized clinical trials and the findings extended to mobilization of CD34(+) stem cells, ex vivo expansion techniques, and use in platelet abnormalities.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 02:07:27